Catechol-O-Methyltransferase Inhibitors in Parkinson's Disease Management
Summary
Catechol-O-methyltransferase (COMT) inhibitors represent a cornerstone in the pharmacological management of Parkinson’s disease, acting to prolong the central availability of levodopa by blocking its peripheral and central enzymatic degradation. By inhibiting COMT, these agents—among which tolcapone, entacapone and the newer compound opicapone are most widely used—attenuate motor fluctuations and dampen end-of-dose “wearing-off” phenomena. The development of COMT inhibitors has sought to balance efficacy in extending ON-time against safety concerns, notably hepatic monitoring for tolcapone and dopaminergic dyskinesia. Advances in molecular design and dosing regimens aim to optimise bioavailability and minimise adverse events, while real-world practice underscores the importance of individualising therapy according to disease stage, concomitant therapies and patient tolerance. Globally, COMT inhibitors have been integrated into standard treatment algorithms to enhance motor control, improve quality of life and reduce levodopa dose requirements, reinforcing their value as adjunctive therapies in modern Parkinson’s disease care.
Research from Nature Portfolio
No recent Nature Portfolio content available.
Catechol-O-Methyltransferase Inhibitors in Parkinson's Disease Management publication trend
The graph below shows the total number of articles in catechol-o-methyltransferase inhibitors in parkinson's disease management across all publications each year (not limited to Nature Index journals).
Technical terms
Catechol-O-Methyltransferase (COMT) Inhibitor: A drug that blocks the enzyme COMT, slowing levodopa metabolism and extending its therapeutic effect.
Levodopa: The primary dopamine precursor used to replenish striatal dopamine in Parkinson’s disease.
OFF-time: Periods during which medication efficacy wanes and parkinsonian symptoms re-emerge.
ON-time: Periods during which motor function is optimally controlled by dopaminergic therapy.
Dyskinesia: Involuntary, erratic movements often arising as a side effect of long-term levodopa therapy.
References
- Opicapone for the treatment of early wearing-off in levodopa-treated Parkinson’s disease: pooled analysis of patient level data from two randomized open-label studies. Journal of Neurology (2024).
- Clinical benefit of MAO-B and COMT inhibition in Parkinson’s disease: practical considerations. Journal of Neural Transmission (2023).
- Safety and efficacy of tolcapone in Parkinson’s disease: systematic review. European Journal of Clinical Pharmacology (2021).
Turn complex research questions into confident strategic decisions
When you're under pressure to set direction, justify investment, or understand your competitive position, you need more than raw data — you need trusted insights you can act on.
Benchmark your performance against global peers using robust, methodologically sound analysis.
Combine quantitative metrics with qualitative expert insight to uncover strengths, gaps and emerging opportunities.
Gain tailored, decision-ready recommendations aligned to your strategic priorities.
Talk to us to learn more about our data dashboards and bespoke strategy reports.
Grow research skills, confidence and careers with training built for every stage of the research lifecycle.
Developed with Nature Portfolio journal Editors and internationally renowned experts. Discover three ways to learn:
Self-paced, online courses in convenient bite-sized units, covering key skills across scientific writing, publishing, grant writing, data analysis, and more.
Expert trainer-led workshops with hands-on exercises and real-time feedback across core research skills, delivered via interactive group sessions.
Editor-led workshops combining core principles in writing and publishing, personalised 1:1 feedback from Nature Portfolio Editors and hands-on exercises.
Explore course catalogues and workshop agendas, enquire about the options or request institutional pricing.